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ABSTRACT
The pandemic caused by the novel coronavirus 
SARS- CoV-2 has placed an unprecedented burden on 
healthcare systems around the world. In patients who 
experience severe disease, acute respiratory distress is 
often accompanied by a pathological immune reaction, 
sometimes referred to as ‘cytokine storm’. One hallmark 
feature of the profound inflammatory state seen in 
patients with COVID-19 who succumb to pneumonia 
and hypoxia is marked elevation of serum cytokines, 
especially interferon gamma, tumor necrosis factor alpha, 
interleukin 17 (IL-17), interleukin 8 (IL-8) and interleukin 6 
(IL-6). Initial experience from the outbreaks in Italy, China 
and the USA has anecdotally demonstrated improved 
outcomes for critically ill patients with COVID-19 with the 
administration of cytokine- modulatory therapies, especially 
anti- IL-6 agents. Although ongoing trials are investigating 
anti- IL-6 therapies, access to these therapies is a 
concern, especially as the numbers of cases worldwide 
continue to climb. An immunology- informed approach 
may help identify alternative agents to modulate the 
pathological inflammation seen in patients with COVID-19. 
Drawing on extensive experience administering these 
and other immune- modulating therapies, the Society 
for Immunotherapy of Cancer offers this perspective 
on potential alternatives to anti- IL-6 that may also 
warrant consideration for management of the systemic 
inflammatory response and pulmonary compromise that 
can be seen in patients with severe COVID-19.
IntroduCtIon
Coronaviruses are a family of enveloped, 
positive sense, single- strand RNA viruses that 
infect mammals and birds. In humans, coro-
navirus infections typically cause mild respi-
ratory disease, including seasonal colds, yet 
some members of the family can be highly 
virulent. In December 2019, a novel coro-
navirus, SARS- CoV-2, structurally related to 
the virus that causes severe acute respiratory 
syndrome (SARS) and Middle East respiratory 
syndrome (MERS), was identified in Wuhan, 
China. Its efficient transmission (R0 of 2.2) 
facilitated its spread across the globe, with 
the first detected case in the USA reported on 
January 19, 2020.1 On March 11, 2020, WHO 
declared the outbreak a pandemic.2
The ongoing COVID-19 outbreak is chal-
lenging every aspect of daily life, including 
the implementation of public health policy, 
the nature of social interactions, adaptation 
of the workforce to a ‘new normal’ and the 
medical research and clinical care infra-
structure, including the care for oncology 
patients. Economic forecasts are concerning, 
and a global financial crisis is anticipated. 
Mathematical modeling based on available 
data shows that in the face of rapid geograph-
ical spread and a high case- fatality ratio, even 
the most advanced healthcare systems are 
very likely to be overwhelmed in the coming 
weeks and months.3 It will be critical to iden-
tify therapies with low barriers to rapid clin-
ical deployment.
It is becoming apparent that in some 
patients, severe COVID-19 disease occurs, and 
is accompanied by a fulminant and damaging 
immune reaction, sometimes called the ‘cyto-
kine storm’, characterized by pronounced 
infiltration of macrophages and mono-
cytes into the alveolae, a pro- inflammatory 
T- helper 17 (Th17) response, and elevated 
levels of inflammatory cytokines, particularly 
IL-6, IL-1β, IL-8, interferon gamma (IFNγ) 
and tumor necrosis factor alpha (TNFα).4–7 
This pro- inflammatory cytokine profile has 
been with poor prognosis and severe lung 
pathology characterized by interstitial mono-
nuclear inflammatory infiltrates, diffuse alve-
olar damage, hyaline membrane formation 
and pulmonary edema.8–10
As the oncology community rallies 
behind our colleagues in intensive care, 
internal medicine, emergency medicine and 
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infectious disease, the immunotherapy field is poised to 
offer insights into the application of immune- modulatory 
therapies. Modulation of IL-6, in particular, which has 
emerged as a potentially promising option for COVID-
19- related acute respiratory distress syndrome (ARDS), 
is used for the treatment of some rheumatological disor-
ders,11 and has become a mainstay in recent years in the 
management of cytokine release syndrome (CRS) after 
chimeric antigen receptor (CAR) T cell therapy for hema-
tological malignancies.12–14 Although the cytokine levels 
observed in patients with COVID-19 experiencing ARDS 
are much lower than those seen in CRS after delivery 
of CAR Tcell therapies and CD3- based bispecific Tcell 
engagers, the cancer immunotherapy community’s expe-
rience in using the IL-6 receptor antagonists to modulate 
severe inflammatory pathology in the setting of CRS may 
prove to be useful in identifying therapies that could be 
of use in this setting.
Healthcare and research organizations continue to 
aggressively pursue development of a vaccines and effec-
tive therapeutic strategies to attenuate the burden of 
SAR- CoV-2 (including antimalarial, antimicrobial and 
directed antiviral agents as well as convalescent serum 
from patients who have cleared virus and recovered) 
and to support patients through the severe inflamma-
tory response and pulmonary complications that can 
frequently occur. The aim of this analysis is to describe 
available strategies that could alleviate the burden on the 
healthcare system with a specific emphasis on therapeu-
tics that could block or modulate the systemic inflamma-
tory response and pulmonary complications caused by 
COVID-19, in particular, IL-6, IL-1 and TNFα pathways.15
ratIonale for targetIng Il-6
SARS- CoV-2 causes the emergent respiratory disease 
called COVID-19. One of the challenging aspects in 
management of the infection is that different presenta-
tions have been identified16:
 ► Asymptomatic carrier state
 ► Mild respiratory symptoms, not requiring 
hospitalization
 ► Recovered and re- examined positive for SARS- CoV-2 
nucleic acid after discharge
 ► Acute respiratory disease: respiratory presentation 
(fever, cough, dyspnea), without radiological evidence 
of a parenchymal process. Additional symptoms may 
include myalgias, headache, sore throat, anosmia, 
chills, diarrhea, nausea and vomiting.
 ► Severe respiratory disease: pneumonia, often bilateral, 
which can progress in severity ultimately requiring 
mechanical ventilation and intensive care manage-
ment. While ARDS is the common feature in patients 
with severe disease, other manifestations have been 
described, such as acute cardiac injury, acute kidney 
injury, coagulopathy and shock.17
 ► Lethal infection: the case- fatality rate has been 
reported from 0.1% to 2%, although complete 
epidemiological analysis is ongoing worldwide and 
facing the challenge of testing availability. Death is 
typically due to massive alveolar damage and irrevers-
ible respiratory failure.18
Almost 75% of patients with COVID-19 acute respira-
tory disease present with abnormal findings on chest 
CT scans. Ground- glass opacities are the most common 
finding, reported in as many as 60% of patients. Other 
findings include patchy infiltrates, and interstitial lung 
disease, although some patients present with minimal 
imaging abnormalities.5 7 17 19
Pathological findings resemble those seen in SARS and 
MERS: edema, proteinaceous exudates, focal reactive 
pneumocyte type II hyperplasia, patchy cellular inflam-
mation and multinucleated giant cells.9 Notably, neutro-
phil infiltration is not significant.20
Elevated C reactive protein (CRP) and elevated aspar-
tate transaminase are common in patients with COVID-19 
and reports from Hubei province in China indicate that 
severe cases are associated with elevated levels of inflam-
matory markers including serum d- dimer, ferritin and 
lactate dehydrogenase.21 The cytokine profile of severe 
COVID-19 disease is characterized by elevated IL-2, IL-6, 
IL-7, IL-8, granulocyte- colony stimulating factor, IL-17, 
TNFα and other markers that indicate systemic inflam-
matory response,22 similar to what has been described 
in macrophage activation syndrome (MAS) or in 
hemophagocytic lymphohistiocytosis (HLH).23 24 More-
over, a retrospective multicenter study of 150 patients 
performed from Wuhan, China suggested that among 
other clinical parameters, CRP and IL-6 levels can be 
predictors of mortality. Among 68 patients who died, 
median IL-6 level was 11.4 ng/mL as opposed to 6.8 ng/
mL in those 82 who survived (p<0.001).25 Additionally, an 
elevated neutrophil- to- leukocyte ratio was also predictive 
of poor prognosis.
In the USA, anticipated shortages of key resources 
including intensive care unit (ICU) beds and mechan-
ical ventilators has led to the implementation of social 
distancing measures to avoid overloading a medical system 
that is not prepared to care for an overwhelming number 
of affected individuals.26 While a concerted effort to 
increase and coordinate the supply of personal protective 
equipment for healthcare workers as well as mechanical 
ventilators for patient care is clearly needed,27 a comple-
mentary approach to decrease the number of patients 
with severe disease, and/or decrease the time required in 
the ICU on a ventilator is important as well.
Based on emerging information as centers gain more 
experience treating SARS- CoV-2- infected patients, modu-
lating or inhibiting the IL-6 signaling pathway to mitigate 
the inflammatory response related to COVID-19 is an 
attractive idea.15 There is a successful precedent for this 
strategy, as it is almost routinely considered in patients 
receiving T cell engaging therapies, such as CAR T cells 
or blinatumomab. In these contexts, IL-6 levels peak at 
the time of maximal T cell proliferation and patients 
may develop a CRS that can be quite severe and even 
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life- threatening.14 Administration of IL-6 blocking agents 
such as tocilizumab and siltuximab has been shown to be 
effective in reversing CRS in these patients.28–30 Tocili-
zumab was approved by the Food and Drug Administra-
tion (FDA) for the treatment of CRS secondary to CAR T 
cell therapy in 2017,13 and incorporated into the risk eval-
uation and mitigation strategies for the approved CAR T 
cell therapy products, tisagenlecleucel and axicabtagene 
ciloleucel.
A word of caution should be exercised in extrapolating 
the adoptive cell transfer experience using IL-6 inhibition 
to COVID-19, as formal comparative analysis of the levels 
of pro- inflammatory cytokines in both situations has not 
yet been performed. Initial data from the COVID-19 
pandemic indicate that cytokine levels are far lower in the 
context of SARS- CoV-2 infection than seen in CRS.25 31
A 21- patient observational study recently performed 
in China supports the use of tocilizumab to avoid rapid 
clinical deterioration of individuals with severe pneumo-
nitis and pulmonary complications.32 Anecdotal cases 
reported in Italy33 also point that tocilizumab may be clin-
ically active in decreasing the magnitude of the inflam-
matory response associated with COVID-19, with rapid 
improvements observed in critically ill patients, even those 
requiring mechanical ventilation. On March 19, 2020, 
the Italian Medicines Agency announced the launch of 
TOCIVID-19, an independent phase II study to evaluate 
the efficacy and safety of tocilizumab in the treatment of 
pneumonia during COVID-19. Accrual of 330 patients 
was reached within 24 hours. In the USA, a randomized, 
double- blind, placebo- controlled phase III clinical trial 
has recently been approved by the US FDA to evaluate 
the efficacy of tocilizumab plus standard of care in hospi-
talized adult patients with severe COVID-19 pneumonia 
(NCT04320615). A randomized, placebo- controlled 
phase II/III study evaluating the efficacy of low- dose and 
high- dose sarilumab, another IL-6- modulating therapy in 
hospitalized patients with COVID-19 against placebo is 
also ongoing (NCT04315298).
Multiple doses of tocilizumab may be necessary for 
maximal benefit. In the Chinese study protocol, patients 
received 400 mg once through an intravenous drip up to 
a maximum of 800 mg with an optimal dose of 8 mg/kg 
body weight. In cases of fever within 12 hours after the 
first administration, an additional dose of up to the same 
amount as the first would be given, with two doses as 
the cumulative upper limit. The protocol for the Italian 
trial, calls for doses comparable to those commonly used 
for the management of CRS, namely, 8 mg/kg (up to a 
maximum of 800 mg per dose), with a second administra-
tion of the same dose given after 12 hours if respiratory 
function has not recovered, at discretion of the inves-
tigator. In preliminary reports from Italy, meaningful 
effects have also been observed with the subcutaneous 
formulation of tocilizumab.
A key lesson learned from the experience of treating 
about 500 severe or critical patients in China is the neces-
sity of starting tocilizumab therapy as soon as possible, 
ideally before symptoms start to rapidly deteriorate at 
the onset of the cytokine storm. It is critical to observe 
high- risk cases, patients with persistent fever, diffuse lung 
opacities on CT scans and elevated serum CRP and IL-6 
(if cytokine measurements are available). Because the 
condition can quickly change from mild to severe, early 
intervention should be strongly considered.
While establishing new indications for an agent gener-
ally requires evaluation in a rigorous, often randomized 
clinical trial, the massive impact of this pandemic, and the 
lack of any existing standard- of- care might provide appro-
priate context to consider off- label use of IL-6 inhibition 
for severely ill patients affected by COVID-19. China’s 
National Health Commission has recently issued updated 
treatment guidelines that include the use of tocilizumab 
in patients with severe disease.34
The FDA is closely monitoring the medical product 
supply chain,35 and the demand for drugs used to treat 
patients with COVID-19 including but not limited to 
tocilizumab, could surpass the ability to manufacture 
these agents. Additionally, in some cases, access to tocili-
zumab and sarilumab is limited despite adequate supply. 
For example, the study protocol for sarilumab in COVID-
19- related ARDS initially excluded individuals who have 
recently been treated with any other investigational drugs, 
high- dose steroids or cyclophosphamide chemotherapy—
effectively preventing numerous patients with cancer and 
patients receiving immunotherapy from receiving this 
potentially lifesaving intervention—however, amended 
exclusion criteria may relax these requirements. Ongoing 
and future clinical trials should consider the unique char-
acteristics of oncology patients in their design (including 
inclusion and exclusion criteria), in light of the fact that 
the large, immune- suppressed population of patients with 
cancer may be particularly susceptible to severe complica-
tions of COVID-19.36 In addition, although data are not 
available, it is unknown whether pulmonary manifesta-
tions of COVID-19 may be potentiated or attenuated in 
oncology patients being treated with immunotherapeutic 
approaches that themselves can have significant pulmo-
nary toxicity, including checkpoint inhibitors and CAR T 
cells.
Although tocilizumab and sarilumab are presently 
the most well- studied anti- IL-6 agents in the COVID-19 
setting, numerous agents have been developed to modu-
late pro- inflammatory signaling at multiple levels in the 
pathway. An immunology- informed approach could iden-
tify potential alternatives to tocilizumab and sarilumab, 
broadening the population of patients that may receive 
treatment to ameliorate the complications of COVID-
19, and thus ‘flattening the curve’ for total patient days 
requiring ICU support, including mechanical ventilation.
overvIew of Il-6 sIgnalIng and regulatIon
IL-6 is a pleiotropic cytokine with nearly ubiquitous expres-
sion in stromal and immune cells. In the airway, alve-
olar macrophages produce IL-6, and expression may be 
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induced in epithelial cells by IFNγ and danger- associated 
molecular patterns (DAMPs).37 38 The effects of IL-6 
are context- specific and may be both pro- inflammatory 
and anti- inflammatory. Although IL-6 is essential for 
both innate and adaptive immunity—patients with auto- 
antibodies to the cytokine or germline mutations in its 
downstream signaling effectors are susceptible to recur-
rent infections and often die prematurely due to pneu-
monia. In turn, uncontrolled IL-6 expression leads to 
profound inflammatory damage to host cells.11 39 Under 
homeostatic conditions, serum concentrations of IL-6 
are typically lower than picograms per mL, but under 
conditions of severe inflammation, levels may reach up 
to nanograms per mL, as seen in severe CRS31 or even 
micrograms per mL in fatal sepsis.40
regulation of Il-6 expression
Expression of IL-6 is regulated at multiple levels including 
chromatin accessibility, transcription, mRNA export, 
post- transcription and translation. TNFα and IL-1β also 
induce IL-6 expression.41 Coronavirus’ spike proteins 
have also been shown to directly promote IL-6 produc-
tion in immune and epithelial cells. Cultured SARS- CoV- 
infected bronchial epithelial cells secrete IL-6,42 and 
murine macrophages upregulate IL-6 and TNFα through 
a nuclear factor-κB- dependent pathway in response to 
viral S protein.43
Il-6 signaling (classical and trans)
Signaling through the IL-6 receptor requires assembly at 
the cell membrane of a complex consisting of IL-6 bound 
to both the 80 kDa type 1 cytokine a- receptor subunit (IL- 
6R, also called CD126) and a 130 kDa signal- transducing 
b- receptor glycoprotein (gp130; also called CD130). This 
trimeric complex homodimerizes, leading to receptor 
activation.11 44 Expression of the membrane- bound 
form of IL- 6R is largely restricted to hepatocytes, mega-
karyocytes and leukocytes,45 yet two independent path-
ways generate a soluble form of the receptor: cleavage 
by membrane metalloproteinases, primarily ADAM10 
and ADAM17, as well as alternative splicing.45–47 Soluble 
IL-6/IL- 6R receptor complex can also bind gp130, acti-
vating the downstream signaling cascade. The ubiqui-
tous expression of gp130, which has been detected in all 
human tissues examined, underlies the pleiotropic effects 
of IL-6, and the near universal responsiveness to the cyto-
kine across cell types. Receptor activation through the 
membrane- bound IL- 6R versus the soluble form of IL- 6R 
are referred to as classical and trans signaling, respec-
tively. Generally, classical signaling contributes to regen-
erative and anti- inflammatory responses, whereas trans 
signaling is pro- inflammatory and plays a role in causing 
tissue damage.
signal transduction
Ligand binding at the IL- 6R activates multiple intracel-
lular signaling cascades, including Janus kinase (JAK)/
signal transducer and activation of transcription (STAT) 
pathways and the phosphatidylinositol 3- kinase (PI3K) 
pathway. Of potential importance in the context of 
COVID-19, the activation of JAK1 and STAT3 kinases 
by IL- 6R initiates a pro- inflammatory transcriptional 
program associated with proliferation, differentiation, 
recruitment, survival and transformation in T and B 
cells and myeloid cells.11 44 45 An overview of IL-6 signal 
transduction with modes of action of approved IL-6- 
modulatory therapies is illustrated in figure 1.
PotentIal theraPeutIC strategIes
IL-6 blocking agents have been developed in the recent 
years to treat rheumatological conditions. Tocilizumab 
was approved by the FDA in 2010 to treat moderately to 
severely active rheumatoid arthritis. While other indica-
tions followed, it was not until August 2017 that it received 
approval for the treatment of CAR T cell- induced CRS.
Many other agents have since been developed or are 
under investigation to modulate the circulating levels, 
receptor binding and/or biological effects of IL-6. The 
FDA- approved agents are listed in table 1, whereas thera-
pies that are not yet approved, but are in later- stage clin-
ical development are described in online supplementary 
table 1. Caution should be exercised in attempting to 
equate antireceptor and antiligand antibodies. The safety 
and efficacy of some of these agents that have not yet 
achieved regulatory approval has not been established. 
Furthermore, none of the agents has achieved regulatory 
approval for use in patients with COVID-19, although 
China has issued treatment guidelines recommending 
tocilizumab for severe SARS- CoV-2 pneumonia.
As with all immune- modulatory agents, patients treated 
with anti- IL-6/IL- 6R agents are at increased risk for infec-
tions, most commonly by opportunistic bacterial and 
fungal pathogens. Patients with latent tuberculosis are at 
risk of reactivation with IL-6 blockade. Other common 
side effects that may be concern in the COVID-19 setting 
include hypotension, decreased platelet counts, liver 
toxicity, risk of gastrointestinal (GI) perforation and diffi-
culty breathing.
Interleukin-6 antagonists
 ► Tocilizumab (Actemra®, Genentech) is an IL- 6R antago-
nist antibody also known as atlizumab. It is indicated 
for the treatment of rheumatoid arthritis, giant cell 
arteritis, polyarticular juvenile idiopathic arthritis, 
systemic juvenile idiopathic arthritis and CAR- T cell- 
induced severe CRS.
 ► Sarilumab (Kevzara®, Regeneron/Sanofi) is an IL- 6R 
antagonist antibody indicated for the treatment of 
adult patients with moderately to severely active rheu-
matoid arthritis who have had an inadequate response 
or intolerance to one or more disease- modifying anti-
rheumatic drugs.
 ► Siltuximab (Sylvant™, EUSA Pharma) is an anti- IL-6 anti-
body, distinct from tocilizumab and sarilumab, as it 
targets the soluble cytokine and not the receptor. It 
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Figure 1 Interleukin 6 (IL-6) signaling cascade. Antibodies such as tocilizumab, sarilumab and siltuximab inhibit IL-6 signaling 
by antagonizing ligand- receptor engagement, whereas Jakinibs prevent the downstream signaling cascade. The intracellular 
domain of gp130 is constitutively associated with the Janus family tyrosine kinases JAK1 and JAK2. On homodimerization, 
JAKs autophosphorylate and JAK1 phosphorylates 5 tyrosine residues in the cytoplasmic tail of gp130, leading to the activation 
of multiple intracellular signaling cascades. Recruitment and phosphorylation of STAT3 initiates its homodimerization and 
nuclear trafficking, initiating a transcriptional program associated with proliferation, differentiation, recruitment, survival and 
transformation in T and B cells and myeloid cells. A negative feedback loop modulates activation of the IL-6- JAK/STAT cascade, 
as STAT3 upregulates SOCS1 and SOCS3, which directly inhibits the catalytic activity of JAK by binding to phosphorylated 
gp130 at tyrosine 759, and stops JAK activation through direct binding.11 Phosphorylated gp130 is also a binding site for 
SH2 domain tyrosine phosphatase 2 (SHP2), activating a cascade involving RAS, RAF and mitogen- activated protein kinases 
(MAPK), which culminates in the activation of various transcription factors involved in increasing cell growth, antibody synthesis 
and acute phase protein generation. JAK also phosphorylates phosphatidylinositol-4,5- bisphosphate (PIP2), which is then 
phosphorylated by phosphoinositide 3- kinase (PI3K) to become phosphatidylinositol-3,4,5- trisphosphate (PIP3), which then 
phosphorylates PkB/Akt serine/threonine kinase to modulate expression of several genes involved in cellular survival.12
is indicated for the treatment of patients with Castle-
man’s disease. Of note, it was not studied in patients 
with HIV or human herpesvirus-8 (HHV-8) infections 
as preclinical studies showed lack of binding to virally 
produced IL-6. Therefore, it is only indicated in those 
patients who are HIV and HHV-8 negative.
Janus kinase/signal transducer and activation of transcription 
(JaK/stat) inhibitors
While encouraging preliminary results have been 
observed with IL-6 blockade, potential constraints on the 
supply of IL-6/IL- 6R- targeting antibodies may limit access 
to these drugs and the numbers of patients that can 
benefit. In order to expand the spectrum of patients who 
may access IL-6- modulatory therapies, alternative targets 
within the cytokine’s inflammatory signaling cascade 
could be considered.
IL-6 signaling takes place via two mechanisms: binding 
to a higher affinity membrane- bound receptor (classical) 
or soluble IL-6 receptor (trans).41 44 Both lead to activa-
tion of JAK/STAT signaling downstream through JAK1 
and STAT3, on tyrosine phosphorylation on the gp130 
receptor’s cytoplasmic tail. JAK/STAT signaling is also 
activated by other pro- inflammatory cytokines that are 
observed to be elevated in COVID-19, particularly IFNγ 
(although IFN signaling is primarily via STAT1). STATs 
also play important roles in non- canonical cell signaling 
pathways, including activity of non- tyrosine phosphory-
lated STATs, mediation of DNA methylation, regulation 
of cell adhesion and mitochondrial activity.48
Small molecules targeting this pathway have been 
successfully introduced into the clinic, and are a thera-
peutic option in a number of inflammatory processes,49 
including graft versus host disease and HLH.50 51 In 
xenograft models, ruxolitinib was able to prevent CRS 
after CAR Tcell therapy.52 Importantly, a phase III trial 
is being initiated to assess ruxolitinib in combination 
with standard of care compared with standard of care 
alone in patients with severe COVID-19 pneumonia as a 
result of SARS- CoV-2 infection.53 Additionally, a phase II 
single- arm study of fedratinib is planned.
 o
n
 M
ay 8, 2020 by guest. Protected by copyright.
http://jitc.bmj.com/
J Im
m
unother Cancer: first published as 10.1136/jitc-2020-000930 on 7 May 2020. Downloaded from 
6 Arnaldez FI, et al. J Immunother Cancer 2020;8:e000930. doi:10.1136/jitc-2020-000930
Open access 
Table 1 Food and Drug Administration- approved agents: IL-6
Agent Mechanism of action
Commercial 
name Manufacturer Indication(s) Comments
Tocilizumab
Recombinant 
humanized 
monoclonal antibody 
(IgG1)
Binds to both soluble 
and membrane- bound 
IL-6 receptors, and 
inhibits IL-6- mediated 
signaling
Actemra® Genentech Rheumatoid arthritis, giant 
cell arteritis, polyarticular 
juvenile idiopathic arthritis, 
systemic juvenile idiopathic 
arthritis, cytokine release 
syndrome (Tcell induced)
Increases risk of 
serious infections
Sarilumab
Human recombinant 
monoclonal antibody 
(IgG1)
Binds to both soluble 
and membrane- bound 
IL-6 receptors, and 
inhibits IL-6- mediated 
signaling
Kevzara® Regeneron/Sanofi Moderately to severely 
active rheumatoid arthritis 
adults who have inadequate 
response to disease- 
modifying antirheumatic 
drugs
Increases risk of 
serious infections
Siltuximab
Glycosylated human- 
mouse chimeric 
monoclonal antibody 
(IgG1)
Binds to soluble IL-6 
and prevents the 
binding to both soluble 
and membrane- bound 
IL-6 receptors
Sylvant™ Janssen/EUSA 
Pharma UK
Multicentric Castleman’s 
disease
No binding to HHV-8 
and HIV produced 
IL-6 in a preclinical 
study
HHV-8, human herpesvirus-8; IL, interleukin.
The rationale for developing these agents as an option 
to prevent or treat cytokine release in COVID-19 is 
compelling, especially given the relative ease of manu-
facturing small molecules at scale as compared with 
biologics. The safety profiles of JAK inhibitors are gener-
ally manageable and predictable including increased risk 
of viral infections, lower GI complications and anemia and 
leukopenia.54 55 Because IL-6 signaling primarily occurs 
through JAK1, the selectivity of JAK inhibitors should be 
considered before their use for COVID-19. Additionally, 
‘Jakinibs’ are oral tyrosine kinase inhibitors,54 which may 
not be easily administered/absorbed in patients with very 
severe ongoing systemic inflammatory response.
 ► Ruxolitinib (Jakavi/Jakafi®, Incyte) is an oral JAK inhib-
itor with selectivity for JAK1 and JAK2 indicated for 
treatment of intermedia- risk or high- risk myelofi-
brosis, polycythemia vera unresponsive or intolerant 
to hydroxyurea and steroid- refractory graft versus 
host disease in adult and pediatric patients aged 12 
years and older.
 ► Tofacitinib (Xeljanz®, Jakvinus, Pfizer) is an oral JAK 
inhibitor with selectivity for JAK1 and JAK3 indicated 
for the treatment of rheumatoid arthritis, psoriatic 
arthritis and ulcerative colitis. The occurrence of 
serious infections and lymphoid- associated malignan-
cies have led to a current black box warning imposed 
by the FDA.
 ► Baricitinib (Olumiant®, Eli- Lilly) is an oral JAK inhib-
itor with specificity for JAK1 and JAK2 indicated for 
the treatment of adult patients with moderately to 
severely active rheumatoid arthritis who have had an 
inadequate response to one or more TNF antago-
nist therapies. The occurrence of serious infections, 
lymphoma and thrombosis have led to a current black 
box warning imposed by the FDA.
 ► Peficitinib (Smyraf®, Astellas) is an oral pan- JAK inhib-
itor with JAK1, JAK2, JAK3 and tyrosine kinase 2 
activity approved only in Japan and indicated for the 
treatment of rheumatoid arthritis in patients who 
have inadequate response to conventional therapies.
 ► Upadacitinib (Rinvoq™, AbbVie) is a second- generation 
oral JAK inhibitor with high specificity for JAK1 that 
is indicated for the treatment of adults with moder-
ately to severely active rheumatoid arthritis who 
have had an inadequate response or intolerance to 
methotrexate. The occurrence of serious infections, 
lymphoma and thrombosis has led to a current black 
box warning imposed by the FDA.
 ► Fedratanib (Inrebic®, Impact Biomedicines/Celgene) is an 
oral semi- selective JAK2 JAK inhibitor indicated for 
the treatment of adult patients with intermediate or 
high- risk primary or secondary (postpolycythemia 
vera or postessential thrombocythemia) myelofibrosis. 
The occurrence of serious and fatal encephalopathy, 
including Wernicke’s, has led to a black box warning 
imposed by the FDA.
Interleukin-1 inhibitors
Modulation of IL-1 signaling, especially through the IL-1β 
isoform, could also potentially attenuate the exuberant 
inflammatory response that accompanies lung pathology 
in COVID-19 upstream of IL-6. Although serum IL-1 has 
not necessarily correlated with severity of SARS- CoV-2 
disease in published reports, its function as a master 
cytokine elicits large effects with small perturbations.56–58 
IL-1 signaling orchestrates the acute phase of response to 
infections and has also been demonstrated to influence 
the differentiation of lymphocytes, particularly Th17 cells. 
Of the two isoforms, IL-1β is predominantly associated 
with pulmonary pathology in ARDS.59 60 Although data 
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on the immunopathology underlying ARDS in COVID-19 
are lacking, a pro- inflammatory Th17 signature has been 
observed in patients infected with SARS- CoV-261 as well as 
in patients with MERS- CoV.62 Additionally, IL-1 has been 
shown to be a key cytokine driving pro- inflammatory 
activity in bronchoalveolar lavage fluid of patients with 
acute lung injury.60
The IL-1 family of cytokines are major regulators of the 
acute phase response, functioning to control inflamma-
tory reactions in response to PAMPs and DAMPs released 
from damaged or infected cells.57 63 Hundreds of genes 
are transcriptionally upregulated by IL-1 signaling, 
including IL-6. IL-1- modulating therapies have been 
FDA approved for a number of indications, primarily for 
auto- inflammatory diseases where the primary drivers of 
pathology are innate immune cells rather than the T cell 
and Bcell compartments.64 Three IL-1- modulating ther-
apies have been approved by the FDA, and each agent 
inhibits signaling through a distinct mechanism, which 
may have important implications for their possible use in 
treating COVID-19.
Multiple mechanisms modulate IL-1 signaling, 
including the soluble IL-1 receptor antagonist (IL- 1RA), 
which is secreted by immune cells, epithelial cells and 
adipocytes,65 and the decoy receptor IL- 1RII, which 
exists in both membrane- bound and soluble forms and 
scavenges IL-1β with high affinity.66 These endogenous 
factors have formed the basis for several IL-1- targeting 
therapeutics, including anakinra (a receptor antagonist) 
and rilonacept (a receptor trap). Additionally, an anti- 
IL-1β antibody, canakinumab, has been FDA approved 
for a variety of auto- inflammatory diseases.
Anakinra is a recombinant form of IL- 1RA that lacks 
glycosylation and is modified with the addition of a 
single methionine residue at the N- terminus. Although 
several randomized trials failed to demonstrate statis-
tically significant 28- day survival benefits for IL- 1R 
antagonist therapy for sepsis,67–69 a reanalysis showed 
profoundly improved outcomes among the subset of 
patients with disseminated intravascular coagulation 
and hepatobiliary dysfunction, hallmarks of secondary 
MAS.70 Anakinra has also proven effective and gained 
FDA approval for the treatment of a variety of autoin-
flammatory disorders including CAPS as well as rheuma-
toid arthritis.56 63 Anakinra is short- acting, with a plasma 
half- life of roughly 4–6 hours.71
Anecdotal evidence has emerged that anakinra effec-
tively modulates late- onset, tocilizumab- refractory CRS 
with clinical features similar to HLH/MAS secondary to 
CAR T cell therapy.72 Initial experience from the Northern 
Italian SARS- CoV-2 outbreak, however, has indicated that 
anakinra monotherapy did not provide clinical benefit 
when administered to patients with severe ARDS.33 It is 
possible that multiple mechanisms need to be targeted, 
as cytokine profiles from patients with COVID-19 demon-
strate marked elevation of multiple factors beyond IL-1, 
including IL-6, IL-17, TNFα and IFNγ. An ongoing clinical 
trial is evaluating anakinra in combination with the IFNγ 
inhibitor emapalumab for severe ARDS in COVID-19 
(NCT04324021).
The overall safety profile of anti- IL-1 therapies is accept-
able. As with any cytokine modulator, IL-1 blockade carries 
increased risk of bacterial infections, but after many years 
of clinical experience and tens of thousands of patients 
treated, it has become apparent that opportunistic 
infections are highly rare with anakinra treatment, even 
among people at high risk for tuberculosis reactivation. 
Of note, anti- IL-1 therapy is associated with a reduction 
in circulating neutrophil counts,58 which may be clinically 
significant given that a high NLR (Neutrophil to Leuko-
cyte Ratio) is predictive of poor prognosis in COVID-19. 
Evidence for improved outcomes after using IL-1 modu-
lating therapies for CRS is lacking and variable. The 
timing of IL- R1 antagonist administration may be critical, 
and limited benefit may be obtained with treatment of 
already- established ARDS. Targeting IL-1β directly, either 
by reducing its effective concentration via a receptor trap 
or monoclonal antibody may also be impactful.
 ► Anakinra (Kinaret®, Sobi) is a modified, recombinant 
human IL- 1R antagonist indicated for the treatment 
of adult rheumatoid arthritis and neonatal- onset 
multisymptom inflammatory disease.
 ► Rilonacept (Arcalyst®, Regeneron) is a dimeric fusion 
protein consisting of the extracellular domains 
of IL- 1R and IL- 1RAcP, linked by the Fc portion of 
human anti- IL-1 IgG1 indicated for the treatment of 
adults and children 12 years of age and older with 
CAPS.
 ► Canakinumab (Ilaris®, Novartis) is a human mono-
clonal anti- IL-1β antibody indicated for the treatment 
of periodic fever syndromes (including CAPS) and 
systematic juvenile idiopathic arthritis.
tumor necrosis factor alpha inhibitors
Ligands and receptors of the tumor necrosis factor super-
family play central roles in regulation of the immune 
system and tissue homeostasis. Although TNF signaling is 
vital for antipathogen immune responses and is protective 
in a variety of viral infections including smallpox,73 West 
Nile virus74 and influenza,75 elevated levels of TNFα have 
been linked to pulmonary pathology in acute lung injury. 
Elevated TNFα is observed in both plasma and bronchoal-
veolar lavage fluid in patients with ARDS, and expression 
of the cytokine directly leads to increased endothelial 
permeability along with impaired alveolar fluid clearance 
due to downregulation of epithelial sodium channels.76 77 
Elevated serum TNFα has been reported to correlate with 
severe disease in COVID-19,8 and the SARS- CoV S protein 
has been demonstrated to induce TNFα and IL-6 upregu-
lation in murine macrophages.43
The primary sources of TNFα are stimulated mono-
cytes, fibroblasts and endothelial cells, although macro-
phages, T cells, B lymphocytes, granulocytes, smooth 
muscle cells, eosinophils, chondrocytes, osteoblasts and 
mast cells all produce TNFα as well.77–79 TNFα is synthe-
sized as a membrane- protein and cleaved by ADAM17 to 
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release its soluble form. Both the soluble and membrane- 
bound forms of TNFα are active, although their affini-
ties to TNF- family receptors varies. TNFα signaling is 
complex, and may involve as many as 29 different tumor 
necrosis factor receptor (TNFR) family members. In 
particular, TNFR1 is widely expressed; as is the case for 
IL-6 this broad- based expression gives rise to pleiotropic 
systemic effects.
Multiple TNFα inhibitors have been developed for 
the treatment of inflammatory diseases, and some have 
demonstrated benefit in animal models of acute lung 
injury and respiratory distress.80 These results have not 
borne out in humans, however, as anti- TNFα therapy 
failed to protect patients from sepsis- induced acute lung 
injury81 82 and did not improve outcomes for chronic 
obstructive pulmonary disease.83 Preliminary reports 
from China indicate that anti- TNFα antibody offers 
limited benefit for patients with SARS- CoV-2 infec-
tions with established ARDS,84 although modulating 
the pathway through other targets or at different time-
points may be more efficacious. In the oncology setting, 
the anti- TNFα antibody infliximab is commonly used 
for the management of immune- related adverse events 
secondary to immune checkpoint inhibitor therapy. 
Additionally, success has been reported with the use of 
the TNFα receptor trap etanercept for the treatment of 
CRS secondary to CAR T cell therapy85 and in MAS,86 but 
no prospective, large- scale trials have demonstrated effi-
cacy for TNF modulation in the setting of viral cytokine 
storm. Adverse effects of concern for anti- TNFα therapy 
include dampened cell- mediated immune responses. All 
of the approved agents carry black box warning labels for 
increased risk of serious, life- threatening opportunistic 
bacterial and fungal infections and patients with latent 
tuberculosis should not receive these therapies.
 ► Infliximab (Remicade®, Janssen) is a chimeric mono-
clonal anti- TNFα antibody indicated for the treat-
ment of inflammatory bowel diseases in adults and 
children, rheumatoid arthritis, ankylosing spondylitis, 
psoriatic arthritis and plaque psoriasis.
 ► Etanercept (Enbrel®, Amgen) is a receptor trap consisting 
of TNF- R2 fused to IgG1 Fc indicated for the treat-
ment of rheumatoid arthritis, ankylosing spondylitis, 
psoriatic arthritis and plaque psoriasis.
 ► Adalimumab (Humira®, AbbVie) is a human monoclonal 
anti- TNFα antibody indicated for the treatment of 
rheumatoid arthritis, ankylosing spondylitis, Crohn’s 
disease, psoriatic arthritis and plaque psoriasis.
 ► Certulizumab pegol (Cimzia®, UCB) is a human mono-
clonal anti- TNFα antibody conjugated to a 40 kDa 
polyethylene glycol indicated for reducing signs and 
symptoms in Crohn’s disease and the treatment of 
rheumatoid arthritis, ankylosing spondylitis and psori-
atic arthritis.
 ► Golimumab (Simponi®, Janssen) is a human monoclonal 
anti- TNFα antibody indicated for the treatment of 
rheumatoid arthritis, ankylosing spondylitis, psoriatic 
arthritis and Crohn’s disease.
Interferon gamma
IFNγ is a pleiotropic cytokine that plays an essential 
role in multiple phases of immune and inflammatory 
responses. The IFN family of proteins encompasses three 
distinct classes, with variable direct antiviral and immune- 
modulatory activities.87 The IFNγ receptor is expressed 
on both malignant and non- malignant cell populations.88
On receptor binding, IFNγ initiates a signaling cascade 
through JAK1 and JAK2 activation, which leads to STAT1 
homodimerization and nuclear translocation and tran-
scriptional activation of a wide array of IFN- inducible 
genes through the GAS enhancer element.88 89 IFNγ has 
been implicated as an important downstream effector 
cytokine in the antitumor immune response, and in 
the immune response to various infectious pathogens, 
including viruses.90 Although protective in the context of 
antiviral host defense, IFNγ also has been implicated in 
the pathogenesis of ‘cytokine storm’ and in various auto-
immune diseases.91 92 Anti- IFN therapy has been investi-
gated in HLH, rheumatoid arthritis, multiple sclerosis, 
Crohn’s disease and psoriasis.91 93
Elevated serum IFNγ has been associated with severe 
acute respiratory distress in COVID-19.8 21 36 94 Addition-
ally, IFNγ enhances IL-6 production in monocytes95 and 
an IFNγ-related cytokine storm syndrome was reported 
in some patients during the 2003 SARS coronavirus 
outbreak.96 Anti- IFN antibodies have been demonstrated 
to alleviate acute lung injury induced by severe H1N1 
influenza infection in murine models,97 and a trial of the 
human monoclonal anti- IFNγ emapalumab in combi-
nation with the IL-1 receptor antagonist anakinra for 
COVID-19 is ongoing.98
Anti- interferon therapy is approved in the US for the 
treatment of primary HLH. In the pivotal trial for the 
approval of emapalumab for HLH, the most commonly 
reported adverse events included infections, hyperten-
sion, infusion reactions and fever.99
 ► Emapalumab (Gamifant®, Sobi) a human monoclonal 
antibody that binds to soluble and receptor- bound 
forms of IFNγ and is approved for the treatment of 
primary HLH in patients with refractory, recurrent 
or progressive disease or intolerance to conventional 
therapy
granulocyte macrophage-colony stimulating factor
Alveolar macrophages can play a central role in the 
inflammatory pathology of ARDS through the release of a 
wide array of bioactive factors that damage or induce cell 
death in the lung epithelium such as proteases, reactive 
oxygen species, eicosanoids, phospholipids and cytokines 
including IL-1, IL-6 and TNFα.77 100 One key cytokine that 
regulates macrophage number and function is granulo-
cyte macrophage- colony stimulating factor (GM- CSF), a 
monomeric glycoprotein secreted by macrophages, T 
cells, mast cells, natural killer cells, endothelial cells and 
fibroblasts. GM- CSF is upstream of IL-6 and induces an 
inflammatory transcriptional program through JAK/
STAT signaling.101 Inactivation of GM- CSF in CAR T 
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cells dramatically lowers IL-6 and IL-8 secretion102 and 
therapeutic inhibition of GM- CSF reduces CAR T- cell- 
associated CRS in mouse models.103
Initial evidence from a study of 52 patients with 
COVID-19 reported from Wuhan, China, elevated levels 
of circulating GM- CSF were associated with worse clinical 
outcomes.18 22 Additionally, analysis of peripheral blood 
samples from 33 patients with COVID-19 with pneumonia 
found increased numbers of pathogenic Th1 cells (GM- 
CSF+ IFNγ+) and inflammatory monocytes (CD14+ CD16+ 
with high expression of IL-6) in patients admitted to the 
ICU as compared with non- critical patients.104 In early 
April 2020, several studies evaluating anti- GM- CSF anti-
bodies for COVID-19 treatment were initiated in rapid 
succession, including trials of lenzilumab,105 TJM-2,106 
gimsilumab107 and namilumab. One anti- GM- CSF anti-
body, lenzilumab, received emergency investigational 
new drug approval for compassionate use in patients with 
COVID-19. Although the safety profiles of anti- GM- CSF 
antibodies have been acceptable in phase I and phase II 
trials, it is important to note the potential for lung toxici-
ties and pneumonia with these agents.101
 ► Lenzilumab (Humanigen) is a human monoclonal 
anti- GM- CSF antibody approved for compassionate 
use in patients with COVID-19. A phase III trial for 
COVID-19 is ongoing. Lenzilumab was originally 
developed for the treatment of chronic myelomono-
cytic leukemia and has also been evaluated for inade-
quately controlled asthma and rheumatoid arthritis.
 ► Namilumab (Izana Bioscience) is a human monoclonal 
anti- GM- CSF antibody that has been evaluated in 
phase II trials for plaque psoriasis and rheumatoid 
arthritis. It is being evaluated in a two center compas-
sionate use study for COVID-19 by UK- based Izana 
Bioscience. In the rheumatoid arthritis study, a few 
patients experienced AEs indicative of pulmonary 
alveolar proteinosis, but following review all sugges-
tive cases were given an alternative diagnosis.
 ► Gimsilumab (Roivant) is a human monoclonal anti- 
GM- CSF antibody developed for rheumatoid arthritis. 
It has demonstrated favorable safety and tolerability 
with no serious adverse events reported in two phase 
I trials in healthy adult volunteers. Trials in patients 
with COVID-19 will be prioritized instead of a planned 
phase II study in patients with rheumatoid arthritis.
 ► TJM-2 (I- Mab Biopharma) is a neutralizing antibody 
against GM- CSF that is being developed to treat 
cytokine storm in critically ill patients with COVID-19. 
It previously exhibited favorable safety, tolerability, 
pharmacokinetic/pharmacodynamic and immuno-
genicity profiles in a phase I dose- escalation study 
in the USA and received IND (Investigational New 
Drug) clearance from China’s National Medical Prod-
ucts Administration for a multiple- dose phase Ib study 
in patients with rheumatoid arthritis.
 ► Otilimab (GSK) is a human GM- CSF inhibitory anti-
body that started phase III evaluation for rheuma-
toid arthritis in July 2019. During the phase II trials 
of otilimab, no serious adverse events and pulmonary 
toxicity, including pulmonary alveolar proteinosis, 
were observed.
Interleukin-17 and interleukin-23 inhibitors
IL-17 is a pro- inflammatory cytokine. It is produced 
by Th17 cells on stimulation with IL-23. The IL-17/
IL-23 axis stimulates the secretion of cytokines know 
to mediate inflammation, including IL-6, and IL-6 (in 
the presence of TGF-β) skews naïve CD4 T cells toward 
the Th17 phenotype.108 IL-17/IL-23 signaling has been 
postulated to mediate cross- talk between the innate and 
the adaptive immune system.109 A characteristic Th17 
signature has been noted in patients with COVID-19 
ARDS,10 and modulation of IL-17 signaling through 
the JAK/STAT inhibitor fedratinib has been proposed, 
although this indication is currently speculative.61 Clin-
ically, the use of agents that modulate this axis have 
been mostly used in the treatment of chronic conditions 
such as psoriasis109 and the most frequently observed 
adverse events have been nasopharyngitis, upper respi-
ratory tract inflammation and injection site reactions.110 
Although these agents have the potential to dampen 
IL-6 production and signaling, the use of IL-17/IL-23 
modulators in conditions such as CRS has not yet been 
widely tested.
 ► Secukinumab (Cosentyx®, Novartis) is a human IL- 17A 
antagonist indicated for the treatment of moderate- 
to- severe plaque psoriasis, psoriatic arthritis and anky-
losing spondylitis.
 ► Ixekizumab (Taltz®, Eli- Lilly) is a humanized IL- 17A 
antagonist indicated for the treatment of adults with 
moderate- to- severe plaque psoriasis.
 ► Brodalumab (Siliq®, Valeant/LEO Pharma) is a human 
IL-17 receptor A antagonist indicated for the treat-
ment of moderate- to- severe plaque psoriasis. The 
occurrence of suicidal ideation has led to a black box 
warning imposed by the FDA.
 ► Ustekinumab (Stelara®, Janssen) is a human IL-12 and 
IL-23 antagonist indicated for the treatment of adult 
patients with moderate- to- severe plaque psoriasis, 
active psoriatic arthritis and moderately to severely 
active Crohn’s disease.
 ► Guselkumab (Tremfya®, Janssen) is an IL-23 blocker 
indicated for the treatment of adult patients with 
moderate- to- severe plaque psoriasis.
 ► Tidrakizumab- asmn (Ilumya™, Sun Pharma Global) is an 
IL-23 antagonist indicated for adults with moderate- 
to- severe plaque psoriasis.
 ► Risankizumab- rzaa (Skyrizi™, AbbVie) is an IL-23 antag-
onist indicated for the treatment of plaque psoriasis
ConClusIon
The COVID-19 pandemic caused by SARS- CoV-2 high-
lights an urgent need for all healthcare stakeholders 
including government organizations, academic centers, 
community centers, philanthropic organizations, advo-
cates, pharmaceutical and biotechnology industries to 
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develop a coordinated and flexible approach to increase 
the availability of resources.
Modulation/inhibition of the severe inflammatory state 
in patients with COVID-19, characterized by elaboration 
of various inflammatory mediators, including IL-6, is a 
potentially important strategy to treat and/or limit severe 
COVID-19 pulmonary complications, including ARDS. If 
successful across the broader population of patients with 
COVID-19, strategies such as anti- IL-6- directed therapy 
could reduce the needs for ICU support and mechanical 
ventilation, and ultimately decrease mortality.
Randomized phase III trials are currently evaluating 
the efficacy of anti- IL-6- directed agents, including tocili-
zumab and sarilumab, as well as the JAK/STAT inhibitor 
ruxolitinib, and will provide definitive data regarding 
the use of these agents in patients with COVID-19. As 
described here, other anti- IL-6 agents, including small 
molecule inhibitors of IL-6 signaling, and other anticyto-
kine inhibitors may warrant investigation, particularly in 
the setting of overwhelming demand for agents to modu-
late the inflammatory state in patients with COVID-19. 
Ongoing studies are also investigating other strategies, 
such as the use of eculizumab (a monoclonal antibody 
that targets complement protein C5, approved for parox-
ysmal nocturnal hemoglobinuria), or some TLR7-8 inhib-
itors such as M5049. In all likelihood, a combinatorial 
approach encompassing antivirals such as remdesivir and 
potentially cytokine- modulatory therapies may be needed 
to successfully treat the infection with SARS- CoV-2 and 
the full spectrum of associated complications.
The US FDA has announced a new program, CTAP 
(Coronavirus Treatment Acceleration Program), to 
expedite drug development for COVID-19. While this is 
encouraging news and the appropriate way to proceed 
from a drug development perspective, the healthcare 
community and, more importantly, the affected patients, 
need effective treatments without delay, especially as the 
numbers of cases in the USA and several countries around 
the world continue to grow exponentially. Consideration 
also should be given to focus efforts on rapidly expanding 
the ability of clinicians and clinical investigators to access 
investigational anti- IL-6 agents, in particular for those 
agents where phase II and/or phase II studies have been 
completed, and acceptable safety has been demonstrated. 
Use of cytokine- modulatory agents during these extreme 
circumstances may additionally warrant consideration, 
and definitive prospective randomized trials also should 
be conducted with all due haste.
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